Mutant IDH2 Inhibitor Looks Promising in AML

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-nb2014-054
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Induction of Sarcomas by Mutant IDH2

Genes and Development
GeneticsDevelopmental Biology
2013English

Enasidenib, an Inhibitor of Mutant IDH2 Proteins, Induces Durable Remissions in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2019English

RNA Interference Looks Promising Against Bee Colony Collapse Disorder

Microbe
Microbiology
2010English

BCL2/MDM2 Inhibitor Combo Effective in AML

Cancer Discovery
Oncology
2019English

Therapeutic Targeting of Isocitrate Dehydrogenase Mutant AML

Expert Opinion on Investigational Drugs
MedicinePharmacology
2017English

A Selective FLT3 Inhibitor Shows Clinical Efficacy in AML

Cancer Discovery
Oncology
2013English

IDH1 Inhibitor Shows Promising Early Results

Cancer Discovery
Oncology
2014English

Identification of a Selective Inhibitor of IDH2/R140Q Enzyme That Induces Cellular Differentiation in Leukemia Cells

Cell Communication and Signaling
BiochemistryCell BiologyMolecular Biology
2020English

Imidazoquinoxaline Derivative EAPB0503: A Promising Drug Targeting Mutant Nucleophosmin 1 in Acute Myeloid Leukemia

Cancer
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy